SAMSUNG-ELECTRONICS
18.11.2021 11:26:06 CET | Business Wire | Press release
Samsung Electronics, a world leader in advanced semiconductor technology, held its 3rd Annual Samsung Advanced Foundry Ecosystem (SAFETM ) Forum 2021 virtually today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118005659/en/
With the theme of 'Performance Platform 2.0: Innovation, Intelligence, Integration', Samsung and its foundry ecosystem partners prepared 7 plenary talks and 76 technology sessions focused on three main topics: Gate-All-Around (GAA, Innovation), Artificial Intelligence (AI, Intelligence), and 2.5D/3D (Integration) technologies and the diverse design infrastructures required for high-performance applications.
“In the rapidly changing data-centric era, Samsung and its foundry partners have made great strides responding to increasing customers demand and to support their success by providing powerful solutions,” said Ryan Lee, Senior Vice President and Head of Foundry Design Platform Development at Samsung Electronics. “With the support of our SAFE program, Samsung will lead the realization of the vision 'Performance Platform 2.0'.”
Starting with a keynote live streaming on November 17, attendees are able to explore a variety of tech sessions and engage with ecosystem partners through the virtual SAFE Forum platform for a month. To register for SAFE forum, please visit https://www.samsungfoundry.com
SAFE 2021: Performance Platform 2.0
Samsung has concentrated on expanding its foundry ecosystem by focusing on IP, Electronic Design Automation (EDA), Cloud, Design Solution Partner (DSP), and Package solutions necessary for today’s data-driven era. Samsung introduced today its latest SAFETM program including:
- SAFE™-IP & EDA: Samsung and its foundry ecosystem have reserved over 3,600 IPs and 80 certified EDA tools respectively. These are developed and verified based on the high-standard of certification program run by Samsung and participated in by our partners. In order to respond to the demands of high performance applications, Samsung’s foundry ecosystem has developed not only HPC-specific foundation IPs including standard cell libraries and memory compilers but also key IPs, such as over 100Gbps Serializer-Deserializer (SerDes) interface and 2.5D/3D multi-die integration solutions.
With our EDA partners, Samsung has secured design tools optimized for its unique 3-nanometer (nm) GAA process technology and design methodology for integrating multiple dies in 2.5D/3D. Customers can also utilize AI- and machine learning- based EDA technology to systematically manage and analyze design data. To overcome the increasing difficulties of chip design and analysis, Samsung has strengthened cooperation with partners to develop EDA tools and related technologies, such as incorporating GPUs that can efficiently use computing resources required for chip verification.
- SAFE™-OSAT: Samsung plans to lead ‘beyond-Moore’ technologies by strengthening various package line-ups such as 2.5D/3D through the expansion of its SAFE-Outsourced Semiconductor Assembly and Test (OSAT) ecosystem. The recent announcement of the co-development of Hybrid-Substrate Cube (H-Cube) solution, which offers efficient integration of 6 HBMs and cost benefit, is one of the successful examples of Samsung foundry’s collaboration with the OSAT community.
-
SAFE™-Cloud Design Platform
: SAFE™-CDP, the cloud-based one-stop design platform introduced last year, now supports a hybrid cloud function that can be linked to customers' conventional design environments.
- SAFE™-DSP : Through the SAFE™-DSP ecosystem, Samsung and its global partners can actively support global fabless companies to implement their design ideas into custom product by utilizing cutting-edge process technologies as well as high-performance, low-power chip design knowledge.
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com
Quote from SAFETM Partner companies
- Ansys, Ajei Gopal, CEO
“Today’s chips demand a full multiphysics approach, which requires engineering simulation. Ansys is proud to partner with Samsung to deliver a comprehensive multi-physics analysis flow for Samsung’s multi-die integration initiative. The benefits to joint customers, to the industry – and to the entire world – are tremendous. Semiconductors will drive innovations as varied as autonomous and electric vehicles, artificial intelligence, and mobile technologies, including 5G and beyond.”
- Arm, Simon Segars, CEO
“Our longstanding partnership with Samsung Foundry has been essential for growing business opportunities in many markets for our combined partner ecosystem. This close collaboration continues as we work together to optimize our Armv9 next-generation processors on Samsung Foundry’s leading-edge processes, including GAA, to deliver a best-in-class solution that is optimized for the world of today, and the technologies of tomorrow. Together, we are unlocking new opportunities across HPC, Automotive, AI, and IoT, while also managing rising complexities, enabling faster time to market.”
- Cadence, Lip-Bu Tan, CEO
“The Cadence Intelligent System Design strategy is very well-aligned with Samsung Foundry’s Performance Platform 2.0 with common themes of innovation, pervasive intelligence and integrated solutions. Together, we’re enabling customers to develop and deliver innovative, breakthrough products using Samsung’s most advanced process and packaging technologies, and we look forward to continuing our work with Samsung Foundry to accelerate design successes.”
- Siemens EDA, A.J. Incorvaia, Senior Vice President
“Quo The Samsung SAFE event provides an exceptionally valuable venue for the Samsung Foundry ecosystem to meet, share information and identify opportunities to fully leverage Samsung’s cutting-edge process technologies. Siemens EDA looks forward to this year’s Samsung SAFE event and the many opportunities it presents for collaborating with customers and partners to eliminate design obstacles and enhance silicon success.”
- Synopsys, Sassine Ghazi, president and COO
“We see exciting times ahead as software and chip technology come together to create world-changing new products,” said Sassine Ghazi, president and COO of Synopsys. “We have strong programs with Samsung Foundry on 3nm gate-all-around enablement, broad IP certification, AI-assisted chip design and 2.5/3D multi-die design to name just a few. We welcome the strong collaboration opportunities offered by the Samsung SAFE initiative.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom